Healthy IndividualsPhase 1NCT07025759
Effects of Peripheral Magnetic Stimulation on Cortical Excitability in Healthy Individuals
A Phase 1 study testing Peripheral magnetic stimulation (90% of RMT + 1 Hz), Peripheral magnetic stimulation (90% of RMT + 10 Hz) and Peripheral magnetic stimulation (90% of RMT + 25 Hz) in people with Healthy Individuals, run by Universidade Federal de Pernambuco at 1 site in Brazil.
Trial summary
This study investigates the immediate effects of different parameters (frequency, intensity, and pulse number) of peripheral magnetic stimulation (rPMS) on cortical excitability in healthy individuals. Read more about this study
- Who is it for?
- Ages 18 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Individuals
- What is being tested?
- Peripheral magnetic stimulation (90% of RMT + 1 Hz), Peripheral magnetic stimulation (90% of RMT + 10 Hz) and Peripheral magnetic stimulation (90% of RMT + 25 Hz)
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 18 participants
- Where
- 1 siteBrazil
- Study dates
- 1 Oct 2022to Oct 2025
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- All sexes
- Healthy volunteers accepted
- Adult
Inclusion criteria: Healthy adults aged 18-40 years, both sexes, right-handed (confirmed via Edinburgh Handedness Inventory), and for females, consistent use of contraceptive medication to mitigate hormonal influences on nervous system excitability.
Exclusion criteria: Pregnancy; history of seizures or epilepsy; metallic implants in the head, spine, face, or heart; diagnosed neurological or musculoskeletal conditions interfering with assessments or interventions; or use of substances altering nervous system excitability.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Brazil1 site, 1 recruiting
- Recruiting
Universidade Federal de Pernambuco
Recife, Pernambuco
Monte-Silva, +55 81 21267579, lana.ufpe@gmail.com
About this study
This study investigates the immediate effects of different parameters (frequency, intensity, and pulse number) of peripheral magnetic stimulation (rPMS) on cortical excitability in healthy individuals. Using a randomized, double-blind crossover design, the research aims to identify optimal stimulation protocols for modulating neural activity. Outcomes include measurements of motor-evoked potentials (MEPs), intracortical inhibition (ICI), and facilitation (ICF). Findings may enhance non-invasive therapeutic strategies for neurological disorders.
Read the detailed description
This clinical trial is a crossover trial comparing 9 single-session rPMS protocols over the extensor carpi radialis muscle, testing three frequencies (1Hz, 10Hz, 25Hz), intensities (90%, 100%, 110% of resting motor threshold) across sequential phases.
Participants: Healthy adults (18-40 years) undergo pre-/post-intervention assessments: cortical (MEPs, ICI/ICF) excitability.
Design: Crossover, double-blind.
Analysis: ANOVA or Friedman tests (SPSS v20.0; α=0.05).
Significance: Clarifies parameter-specific neuromodulatory effects, guiding future rehabilitation protocols for neurological conditions.
Ethics: Approved by Federal University of Pernambuco's ethics committee (Resolution 466/12). Data stored securely for 5 years.
- Conditions
- Healthy Individuals
- Being tested
- Peripheral magnetic stimulation (90% of RMT + 1 Hz), Peripheral magnetic stimulation (90% of RMT + 10 Hz), Peripheral magnetic stimulation (90% of RMT + 25 Hz), Peripheral magnetic stimulation (100% of RMT + 1 Hz), Peripheral magnetic stimulation (100% of RMT + 10 Hz)
- Keywords
- Peripheral Magnetic Stimulation, Cortical Excitabilty
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Peripheral magnetic stimulation (90% of RMT + 1 Hz)Device
Low-frequency stimulation (1 Hz) at 90% of resting motor threshold intensity, delivering a total of 2400 pulses.
Peripheral magnetic stimulation (90% of RMT + 10 Hz)Device
High-frequency stimulation (10 Hz) at 90% of resting motor threshold intensity, totaling 2400 pulses.
Peripheral magnetic stimulation (90% of RMT + 25 Hz)Device
High-frequency stimulation (25 Hz) at 90% of resting muscle threshold intensity, with 2400 pulses.
Peripheral magnetic stimulation (100% of RMT + 1 Hz)Device
Low-frequency (1 Hz), at resting motor threshold intensity (100%) protocol delivering 2400 pulses.
Peripheral magnetic stimulation (100% of RMT + 10 Hz)Device
High-frequency (10 Hz), at resting motor threshold intensity (100%) protocol delivering 2400 pulses.
Peripheral magnetic stimulation (100% of RMT + 25 Hz)Device
High-frequency (25 Hz), at resting motor threshold intensity (100%) protocol delivering 2400 pulses.
Peripheral magnetic stimulation (110% of RMT + 1Hz)Device
Low-frequency (1 Hz), above resting motor threshold intensity (110%) protocol delivering 2400 pulses.
Peripheral magnetic stimulation (110% of RMT + 10Hz)Device
High-frequency (10 Hz), above resting motor threshold intensity (110%) protocol delivering 2400 pulses.
Peripheral magnetic stimulation (110% of RMT + 25Hz)Device
High-frequency (25 Hz), above resting motor threshold intensity (110%) protocol delivering 2400 pulses.
| Study group | Role | What they receive |
|---|---|---|
| Peripheral magnetic stimulation (90% + 1 Hz) | Active comparator | Not described Receives: Device: Peripheral magnetic stimulation (90% of RMT + 1 Hz) |
| Peripheral magnetic stimulation (100% + 25 Hz) | Active comparator | Not described Receives: Device: Peripheral magnetic stimulation (100% of RMT + 25 Hz) |
| Peripheral magnetic stimulation (90% + 25 Hz) | Active comparator | Not described Receives: Device: Peripheral magnetic stimulation (90% of RMT + 25 Hz) |
| Peripheral magnetic stimulation (100% + 1 Hz) | Active comparator | Not described Receives: Device: Peripheral magnetic stimulation (100% of RMT + 1 Hz) |
| Peripheral magnetic stimulation (100% + 10 Hz) | Active comparator | Not described Receives: Device: Peripheral magnetic stimulation (100% of RMT + 10 Hz) |
| Peripheral magnetic stimulation (110% + 1 Hz) | Active comparator | Not described Receives: Device: Peripheral magnetic stimulation (110% of RMT + 1Hz) |
| Peripheral magnetic stimulation (110% + 10 Hz) | Active comparator | Not described Receives: Device: Peripheral magnetic stimulation (110% of RMT + 10Hz) |
| Peripheral magnetic stimulation (110% + 25 Hz) | Active comparator | Not described Receives: Device: Peripheral magnetic stimulation (110% of RMT + 25Hz) |
| Peripheral magnetic stimulation (90% + 10 Hz) | Active comparator | Not described Receives: Device: Peripheral magnetic stimulation (90% of RMT + 10 Hz) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cortical excitabilty
Cortical excitability will be assessed through motor-evoked potentials (MEPs) elicited by single-pulse transcranial magnetic stimulation (TMS) over the primary motor cortex (M1), targeting the first dorsal interosseous (FDI) representation area. The hotspot will be determined as the site producing the largest MEP amplitude at the lowest intensity, with stimulation delivered at 100% of the resting motor threshold (RMT). Additionally, paired-pulse TMS protocols will evaluate intracortical inhibition (ICI) and facilitation (ICF) using conditioning stimuli at 80% RMT (3 ms interstimulus interval for ICI, 10 ms for ICF) and test stimuli at 120% RMT. MEP amplitudes will be recorded via surface electromyography (EMG) from the FDI muscle using bipolar electrode placement, with signals sampled at 20,000 Hz (bandpass 5-10,000 Hz) to capture corticospinal excitability changes across timepoints (baseline, post-intervention, and follow-ups).
Measured: Baseline (T0), immediately post-stimulation (T1), 15 minutes (T2), and 30 minutes (T3) post-stimulation.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jun 2025
- Study start1 Oct 2022
- Primary completionSep 2025 (estimated)
- Study completionOct 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy IndividualsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 18 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Universidade Federal de Pernambuco
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Kátia Monte-Silva, Universidade Federal de Pernambuco
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07025759
- Sponsor's protocol ID
- Parameters_pMS
- Status last verified
- Jun 2025
- First submitted
- 9 Jun 2025
- Last updated
- 17 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Peripheral Magnetic Stimulation on Cortical Excitability in Healthy Individuals
- ClinicalTrials.gov ID
- NCT07025759
- Acronym / sponsor ID
- Parameters_pMS
- Conditions
- Healthy Individuals
- Keywords
- Peripheral Magnetic Stimulation, Cortical Excitabilty
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 18 participants (estimated)
- Lead sponsor
- Universidade Federal de PernambucoUniversity, hospital or other
- Study start
- 1 Oct 2022 (actual)
- Primary completion
- Sep 2025 (estimated)
- Study completion
- Oct 2025 (estimated)
- First posted
- 17 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study investigates the immediate effects of different parameters (frequency, intensity, and pulse number) of peripheral magnetic stimulation (rPMS) on cortical excitability in healthy individuals. Using a randomized, double-blind crossover design, the research aims to identify optimal stimulation protocols for modulating neural activity. Outcomes include measurements of motor-evoked potentials (MEPs), intracortical inhibition (ICI), and facilitation (ICF). Findings may enhance non-invasive therapeutic strategies for neurological disorders.
Detailed description
This clinical trial is a crossover trial comparing 9 single-session rPMS protocols over the extensor carpi radialis muscle, testing three frequencies (1Hz, 10Hz, 25Hz), intensities (90%, 100%, 110% of resting motor threshold) across sequential phases.
Participants: Healthy adults (18-40 years) undergo pre-/post-intervention assessments: cortical (MEPs, ICI/ICF) excitability.
Design: Crossover, double-blind.
Analysis: ANOVA or Friedman tests (SPSS v20.0; α=0.05).
Significance: Clarifies parameter-specific neuromodulatory effects, guiding future rehabilitation protocols for neurological conditions.
Ethics: Approved by Federal University of Pernambuco's ethics committee (Resolution 466/12). Data stored securely for 5 years.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 9
| Arm | Type | Receives |
|---|---|---|
| Peripheral magnetic stimulation (90% + 1 Hz) | Active comparator | Device: Peripheral magnetic stimulation (90% of RMT + 1 Hz) |
| Peripheral magnetic stimulation (100% + 25 Hz) | Active comparator | Device: Peripheral magnetic stimulation (100% of RMT + 25 Hz) |
| Peripheral magnetic stimulation (90% + 25 Hz) | Active comparator | Device: Peripheral magnetic stimulation (90% of RMT + 25 Hz) |
| Peripheral magnetic stimulation (100% + 1 Hz) | Active comparator | Device: Peripheral magnetic stimulation (100% of RMT + 1 Hz) |
| Peripheral magnetic stimulation (100% + 10 Hz) | Active comparator | Device: Peripheral magnetic stimulation (100% of RMT + 10 Hz) |
| Peripheral magnetic stimulation (110% + 1 Hz) | Active comparator | Device: Peripheral magnetic stimulation (110% of RMT + 1Hz) |
| Peripheral magnetic stimulation (110% + 10 Hz) | Active comparator | Device: Peripheral magnetic stimulation (110% of RMT + 10Hz) |
| Peripheral magnetic stimulation (110% + 25 Hz) | Active comparator | Device: Peripheral magnetic stimulation (110% of RMT + 25Hz) |
| Peripheral magnetic stimulation (90% + 10 Hz) | Active comparator | Device: Peripheral magnetic stimulation (90% of RMT + 10 Hz) |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Peripheral magnetic stimulation (90% of RMT + 1 Hz)Low-frequency stimulation (1 Hz) at 90% of resting motor threshold intensity, delivering a total of 2400 pulses. | Device | Peripheral magnetic stimulation (90% + 1 Hz) |
| Peripheral magnetic stimulation (90% of RMT + 10 Hz)High-frequency stimulation (10 Hz) at 90% of resting motor threshold intensity, totaling 2400 pulses. | Device | Peripheral magnetic stimulation (90% + 10 Hz) |
| Peripheral magnetic stimulation (90% of RMT + 25 Hz)High-frequency stimulation (25 Hz) at 90% of resting muscle threshold intensity, with 2400 pulses. | Device | Peripheral magnetic stimulation (90% + 25 Hz) |
| Peripheral magnetic stimulation (100% of RMT + 1 Hz)Low-frequency (1 Hz), at resting motor threshold intensity (100%) protocol delivering 2400 pulses. | Device | Peripheral magnetic stimulation (100% + 1 Hz) |
| Peripheral magnetic stimulation (100% of RMT + 10 Hz)High-frequency (10 Hz), at resting motor threshold intensity (100%) protocol delivering 2400 pulses. | Device | Peripheral magnetic stimulation (100% + 10 Hz) |
| Peripheral magnetic stimulation (100% of RMT + 25 Hz)High-frequency (25 Hz), at resting motor threshold intensity (100%) protocol delivering 2400 pulses. | Device | Peripheral magnetic stimulation (100% + 25 Hz) |
| Peripheral magnetic stimulation (110% of RMT + 1Hz)Low-frequency (1 Hz), above resting motor threshold intensity (110%) protocol delivering 2400 pulses. | Device | Peripheral magnetic stimulation (110% + 1 Hz) |
| Peripheral magnetic stimulation (110% of RMT + 10Hz)High-frequency (10 Hz), above resting motor threshold intensity (110%) protocol delivering 2400 pulses. | Device | Peripheral magnetic stimulation (110% + 10 Hz) |
| Peripheral magnetic stimulation (110% of RMT + 25Hz)High-frequency (25 Hz), above resting motor threshold intensity (110%) protocol delivering 2400 pulses. | Device | Peripheral magnetic stimulation (110% + 25 Hz) |
Primary outcome
Cortical excitabilty
Time frame: Baseline (T0), immediately post-stimulation (T1), 15 minutes (T2), and 30 minutes (T3) post-stimulation.
Cortical excitability will be assessed through motor-evoked potentials (MEPs) elicited by single-pulse transcranial magnetic stimulation (TMS) over the primary motor cortex (M1), targeting the first dorsal interosseous (FDI) representation area. The hotspot will be determined as the site producing the largest MEP amplitude at the lowest intensity, with stimulation delivered at 100% of the resting motor threshold (RMT). Additionally, paired-pulse TMS protocols will evaluate intracortical inhibition (ICI) and facilitation (ICF) using conditioning stimuli at 80% RMT (3 ms interstimulus interval for ICI, 10 ms for ICF) and test stimuli at 120% RMT. MEP amplitudes will be recorded via surface electromyography (EMG) from the FDI muscle using bipolar electrode placement, with signals sampled at 20,000 Hz (bandpass 5-10,000 Hz) to capture corticospinal excitability changes across timepoints (baseline, post-intervention, and follow-ups).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jun 2025.
- Individual participant dataSharing planned: No
Related trials for Healthy Individuals
Recruiting
Investigate the Relationship Between Catastrophizing and the Perception of Itch Intensity in Healthy Individuals
Histamine, Cowhage
Recruiting
Metabolic Impact of VLCPUFA-Rich Fish Oil: A Clinical Study on Omega-3 Index Enhancement in Healthy Individuals
Fatty Acids, Omega-3, Fish Oils
Not yet recruitingObservational study
Microneurographic Assessment of Peripheral Nerves in Healthy Volunteers and Individuals With Sensory Dysfunction Caused by Inherited Mutations in the PIEZO2 Gene
PIEZO2-Deficiency Syndrome
RecruitingObservational study
Studies of Skin Microbes in Healthy People and in People With Skin Conditions
Eczema, Atopic Dermatitis
Active, not recruitingObservational study
C. Difficile Toxin Levels in Stool From Healthy Individuals Following Standard of Care Antibiotic Treatment for CDI.
Clostridioides Difficile Infection Recurrence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Peripheral magnetic stimulation (90% of RMT + 1 Hz), Peripheral magnetic stimulation (90% of RMT + 10 Hz) and Peripheral magnetic stimulation (90% of RMT + 25 Hz) in people with Healthy Individuals, run by Universidade Federal de Pernambuco at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Kátia Monte-Silva (+55 81 21267579, lana.ufpe@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cortical excitabilty (time frame: Baseline (T0), immediately post-stimulation (T1), 15 minutes (T2), and 30 minutes (T3) post-stimulation.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jun 2025.